Search the Newsreel

Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com

Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold shares worth $394,896 in two transactions on August 11 and 12, 2026, following the exercise of stock options. The company's shares have seen a 61.64% return over the past year, and recent Q2 2026 …

Fortress Biotech earnings beat by $0.11, revenue fell short of estimates

Fortress Biotech (NASDAQ:FBIO) Posts Earnings Results, Beats Estimates By $0.12 EPS

Fortress Biotech (NASDAQ:FBIO) announced its quarterly earnings, reporting an adjusted loss of $0.08 per share, surpassing the consensus estimate by $0.12. The biopharmaceutical company also exceeded revenue forecasts with $18.72 million. Despite mixed analyst sentiment and a "Hold" consensus rating, institutional investors own a …

Edesa Biotech Inc reports results for the quarter ended June 30 - Earnings Summary

Edesa Biotech Inc has reported its earnings for the quarter that ended on June 30. The article provides a summary of these results. To access the full details, readers are directed to the complete article available through TradingView, which offers unlimited access to Reuters …

Fortress Biotech 2026: Revenue $17.84M, Net income ($2.48M), EPS ($0.08) — 10-Q Summary

Fortress Biotech (FBIO) reported its financial results for the quarter ended in 2026, showing product revenue of $17.84 million, an 18.9% increase year-over-year. Despite the revenue growth, the company recorded a net loss attributable to common stockholders of ($2.48 million) and a diluted loss …

Edesa Biotech Q3 Results: EPS misses estimate, losses widen 140% YoY

Fortress Biotech: Q2 Earnings Snapshot

Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash

Moleculin Biotech (NASDAQ: MBRX) is progressing with its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed/refractory AML, showing promising preliminary efficacy and cardiac safety data. Despite these clinical advancements and a recent $9.3 million equity/warrant offering, the company reported a net loss of …

Edesa Biotech (EDSA) loss widens to $11.9M as R&D surges and cash tightens

Fortress Biotech (NASDAQ: FBIO) gains $158.9M from voucher sale and boosts cash

Edesa Reports $5.4 Million Q3 Loss as EB06 Phase 2 Site Activation Begins

Edesa Biotech (EDSA) reported a net loss of $5.4 million for Q3 2026, an increase from $1.7 million in the prior year, primarily due to rising operating expenses from its Phase 2 EB06 vitiligo study. The company is beginning site activation for this study …

Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

Edesa Biotech (Nasdaq: EDSA) reported its fiscal third-quarter 2026 results, showing a net loss of $5.4 million due to increased operating expenses. The company announced it has completed preparations for its Phase 2 EB06 vitiligo trial and begun activating initial investigational sites, with patient …

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Fortress Biotech reported a 14% increase in total net revenue to $18.7 million for Q2 2026 compared to Q2 2025, driven by commercial portfolio growth and advancements in partnered programs. Key highlights include Crystalys Therapeutics' $130 million Series B financing for dotinurad, expansion of …

Crystalys Raises $130M to Advance Its Once-Daily Gout Drug

Fortress Biotech (Nasdaq: FBIO) reported a 14% increase in Q2 2026 net revenue to $18.7 million, primarily driven by dermatology product sales. The company's cash and cash equivalents significantly rose to $196.6 million, aided by the monetization of a ZYCUBO® priority review voucher. Key …

PDS Biotechnology (PDSB) cuts R&D spend but warns on going concern, cash at $5.6M

PDS Biotechnology reported a net loss of $17.1 million for the six months ended June 30, 2026, with cash and cash equivalents significantly reduced to $5.6 million from $26.7 million at year-end 2025. The company's management disclosed substantial doubt about its ability to continue …

Renaissance Technologies (BOLT) reports 5.13% ownership stake in Bolt Biotherapeutics

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a 5.13% ownership stake in Bolt Biotherapeutics, Inc., amounting to 98,625 shares. Both entities, based in Delaware, hold sole voting and dispositive power over these shares, with certain managed funds having rights to dividends …

CRCL Stock Hits 3-Month High – CORZ, RIOT Flop Q4 Earnings, DATs Load Crypto

XBiotech: Q2 Earnings Snapshot

This article is an earnings snapshot for XBiotech's Q2 performance. It is a placeholder without actual financial details, suggesting that the full earnings report would contain the relevant financial data.

Trading the Move, Not the Narrative: (VAC) Edition

This article provides an AI-driven analysis for Marriott Vacations Worldwide Corporation (NYSE: VAC), highlighting strong sentiment across all time horizons and compelling upside potential due to the absence of clear resistance levels above the current price. It outlines three distinct institutional trading strategies—Position, Momentum …

PDSB Maintained by HC Wainwright & Co. -- Price Target Lowered t

AQR group (VRXA) discloses 658,138-share Veraxa Biotech position under 5% threshold

AQR Capital Management, along with its affiliates, has reported a beneficial ownership of 658,138 Ordinary Shares in Veraxa Biotech Holding AG, which includes warrants. This position represents 0.46% of Veraxa’s outstanding Ordinary Shares, confirming that the AQR group holds less than the 5% threshold. …

Marriott Vacations Worldwide (VAC) is a Great Momentum Stock: Should You Buy?

Marriott Vacations Worldwide (VAC) is highlighted as a strong momentum stock, earning a Zacks Rank of #1 (Strong Buy) and a Momentum Style Score of B. The article explains that VAC has shown impressive short-term price activity, outperforming its industry and the S&P 500 …

Nanobiotix S.A. (NBTX) investor group reports 9.4% stake and pre-funded warrants

An investor group led by Invus Public Equities, L.P. has reported a 9.4% beneficial ownership stake in Nanobiotix S.A. (NBTX), comprising 4,483,275 ordinary shares and 345,099 pre-funded warrants. The warrants are exercisable at Euro 0.03 per share and expire in May 2036. This filing, …

XBiotech (NASDAQ: XBIT) trims R&D spend yet remains loss-making in Q2 2026

XBiotech Inc. reported a Q2 2026 net loss of $6.7 million and a six-month net loss of $12.2 million, despite significantly reducing research and development and general and administrative expenses. The clinical-stage biopharmaceutical company does not anticipate generating revenue in 2026 and expects continued …

3 Reasons Investors Love Samsara (IOT)

3 Reasons Investors Love Samsara (IOT) What a fantastic six months it's been for Samsara. Shares of the company have skyrocketed 44.3%, hitting $40.04. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the …

Riot Platforms, TeraWulf, Mara Poised to Benefit From Compute Demand, Morgan Stanley Says

Riot Platforms (RIOT), TeraWulf (WULF), and Mara (MARA) are positioned to benefit from continued demand for compute, with recent deals supporting the broader powered shell provider, or PSP, space, Morgan Stanley said in a Thursday research note.The firm said Mara management Silver Upgrade to …

Ajooni Biotech Ltd is Rated Sell

Iovance (IOVA) Q2 2026 Earnings Call Transcript

Iovance Biotherapeutics reported record Q2 2026 revenue of $99.3 million, a 66% year-over-year increase, driven by strong Amtagvi demand and achieving a 56% gross margin. The company is expanding its TIL therapy platform into broader solid tumor indications like non-small cell lung cancer and …

Piper Sandler raises First Tracks stock price target on pipeline progress

Wedbush Issues Positive Forecast for First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Price

PDS Biotechnology reports Q2 2026 net loss $9.8M, cash $5.6M, strategic refocus on PDS0301

PDS Biotechnology reported a net loss of $9.8 million for Q2 2026 and had $5.6 million in cash at quarter-end. The company announced a strategic refocus to prioritize its tumor-targeted IL-12 program, PDS0301, and will discontinue internal investment in PDS0101, seeking external partnerships for …

First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results

HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings

HC Wainwright has lowered its Q3 2026 earnings forecast for Sana Biotechnology (NASDAQ:SANA) to a loss of $0.14 per share, anticipating continued losses through future fiscal years. Despite this, Sana's last quarterly loss of $0.13 per share exceeded analyst expectations. The stock currently holds …

PDS Biotechnology: Q2 Earnings Snapshot

PDS Biotech Reports Second Quarter 2026 Financial Results

PDS Biotechnology Corporation announced its financial results for the second quarter ended June 30, 2026, reporting a net loss of $9.8 million. The company also provided a clinical and corporate update, highlighting positive clinical data for PDS0301 in metastatic colorectal cancer and announcing a …